Leila Jaafar-Thiel

Swiss Nuclides AG provides diagnostics and radiopharmaceutical therapy treatment services for cancer patients. The company is based in Aarau, Switzerland. The Swiss company was founded by Leila Jaafar-Thiel and Gustav von Schulthess, and Leila Jaafar-Thiel has been the CEO since incorporation.

Nuclidium AG is a private company located in Switzerland that is revolutionizing precision oncology by developing copper-based radiopharmaceuticals for targeted cancer treatment and diagnosis. The Swiss company's product portfolio utilizes the unique properties of copper to achieve improved safety and efficacy with advantageous economics for hospitals and patients. The company overcomes supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. Nuclidium's diverse and interdisciplinary team is focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients. The company's flexible CutraCeTM platform combines copper radiometals with highly specific cancer-targeting molecules to rapidly develop novel diagnostic and therapeutic programs. Nuclidium's differentiated "diagnostic to therapeutic" approach de-risks their development pathway.